Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The prognosis of NSCLC patients with asymptomatic brain metastasis, who are not treated with SRS or WBRT has not been fully investigated yet. This randomized phase III trial is conducted to determine the exact role of SRS in NSCLC patients with asymptomatic oligo brain metastases whether early treatment with SRS would improve survival even in patients with asymptomatic brain metastasis.
| Condition | Intervention | Phase |
|---|---|---|
|
Non-small Cell Lung Cancer |
Procedure: stereotactic radiosurgery (SRS) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC) |
- Overall survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- time to CNS progression [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- time to symptomatic brain metastasis [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- quality of life [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- cause of death (neurologic vs. others) [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- neurocognitive function [ Time Frame: 36 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 176 |
| Study Start Date: | June 2008 |
| Estimated Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: stereotactic radiosurgery (SRS) |
Procedure: stereotactic radiosurgery (SRS)
Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
|
| No Intervention: observation |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically confirmed non-small cell lung cancer with synchronous brain metastases (diagnosis of brain lesion before or within 2 months from diagnosis of the primary site tumor)
One to 4 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria:
- Well circumscribed tumor(s) with brain edema Grade 0-1
Maximum diameter ≤ 3.0 cm
No prior complete resection of all known brain metastases or RT ④ No leptomeningeal metastases by MRI or cerebrospinal fluid evaluation
- Patients without any symptoms or signs from brain metastases (RTOG neurologic functions status of 0) ⑥ Age, 18 and over ⑦ ECOG performance status 0-1 ⑧ Written informed consent
Exclusion Criteria:
severe co-morbid illness and/or active infections ② pregnant or lactating women
- RTOG neurologic function status of 1~4 ④ Uncontrollable extracranial metastases
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Myungju Ahn Ph.D., M.D., Samsung Medical Center |
| ClinicalTrials.gov Identifier: | NCT01130766 History of Changes |
| Other Study ID Numbers: | 2009-01-059 |
| Study First Received: | May 25, 2010 |
| Last Updated: | May 25, 2010 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Samsung Medical Center:
|
Non-small Cell Lung Cancer Asymptomatic brain metastasis Stereotactic radiosurgery (SRS) |
Additional relevant MeSH terms:
|
Carcinoma, Non-Small-Cell Lung Lung Neoplasms Neoplasm Metastasis Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Neoplastic Processes Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013